Many patients with treatment-resistant schizophrenia who could benefit from clozapine are not getting it, new research suggests.
A retrospective study shows a "low" initiation rate of clozapine among patients who warrant a trial of the atypical antipsychotic.
"Clozapine is the treatment of choice for someone diagnosed with schizophrenia who isn't responding to other antipsychotics. Lots of people who might benefit from clozapine never try it," Scott Stroup, MD, MPH, of Columbia University Medical Center in New York City, told Medscape Medical News.
Read more: http://www.medscape.com/viewarticle/820547